Chemoradiotherapy Tolerability Results in Geriatric Pancreatic Cancer Patients

Pancreatic cancer poses unique challenges in elderly patients, given comorbidities, performance status concerns, and the absence of clear treatment guidelines. Understanding treatment outcomes and tolerability in this age group is vital. In this retrospective study (2012-2019), 24 elderly pancreatic cancer patients (≥65 years) underwent chemoradiotherapy. Patients were categorized into adjuvant or definitive groups, with overall survival (OS) as the primary endpoint. The median follow-up was 13.57 months; the median age was 71.46±5.55 years. Of these, 9 received definitive chemoradiation, while 15 had surgery followed by chemoradiation. Median OS was 13.07 months (definitive) and 23.4 months (adjuvant) (p=0.061). No significant associations were found between OS and radiotherapy doses, pT stage, pN stage, tumor grade, or presence of invasion/microscopic disease. All completed radiotherapy; no grade 4-5 hematologic toxicity occurred. In conclusion, our findings suggest well-tolerated chemoradiotherapy in elderly patients, supporting its use in both adjuvant and definitive settings within this selected patient group.